Healx is a Cambridge-based biotechnology company that uses artificial intelligence and machine learning to accelerate drug discovery for rare diseases. The company's platform combines AI algorithms with biological data to identify potential drug candidates and repurpose existing drugs for rare disease treatments. Healx focuses on the 7,000+ rare diseases that affect over 400 million people worldwide, many of which have no approved treatments. The company has developed a proprietary AI platform called Healnet that can predict drug efficacy and safety.
Healx has received investment from 1 venture capital firm.
AI-driven drug discovery company focused on finding treatments for rare diseases using machine learning.
Healx has received investment from Cambridge Innovation Capital. These venture capital firms and investors provide both capital and strategic support.
Healx has raised $65M in total funding, with their most recent round being a Series B. The company operates in the Biotech sector.
Healx was founded in 2014 and is headquartered in Cambridge, United Kingdom.
Healx operates in the Biotech sector. AI-driven drug discovery company focused on finding treatments for rare diseases using machine learning.
